Autonomic neuropathy: A marker of cardiovascular risk

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 2, 2003, Pages 84-90

  Kempler, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Alpha lipoic acid; Autonomic neuropathy; Benfotiamin; Cardiovascular reflex tests; Cardiovascular risk; QT interval

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANTIOXIDANT; BENFOTIAMINE; COCARBOXYLASE; GAMMA LINOLENIC ACID; GLUCOSE; PYRIDOXAMINE; THIOCTIC ACID;

AUTONOMIC DYSFUNCTION; AUTONOMIC NEUROPATHY; BLOOD PRESSURE; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR REFLEX; CARDIOVASCULAR RISK; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE MARKER; DISEASE SEVERITY; EXERCISE TOLERANCE; GLUCOSE BLOOD LEVEL; HAND GRIP; HEART ARRHYTHMIA; HEART DISEASE; HEART RATE VARIABILITY; HUMAN; HYPERPNEA; MEDICAL ASSESSMENT; MORTALITY; ORTHOSTATIC HYPOTENSION; PROGNOSIS; QT INTERVAL; RESPIRATORY ARREST; REST; REVIEW; RISK ASSESSMENT; SILENT MYOCARDIAL INFARCTION; STANDING; SUDDEN DEATH; TACHYCARDIA; TREATMENT FAILURE; VALSALVA MANEUVER;

EID: 0041385789     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030020201     Document Type: Review

References (63)

1. Eichorst H. Beiträge zur Pathologie der Nerven und Muskeln. Archiv Pathol Anat Physiol Klin Med 1892;127:1-17.
2. Wieling W, Smit AAJ, Karemaker JM. Diabetic autonomic neuropathy: conventional cardiovascular laboratory testing and new developments. Neuroscience Research Communications 1997;21:67-74.
3. Wheeler T, Watkins PJ. Cardiac denervation in diabetes. BMJ 1973;4: 584-6.
4. Ewing DJ, Campbell IW, Burt AA, Clarke BF. Vascular reflexes in diabetic autonomic neuropathy. Lancet 1973;2:1354-6.
5. Greene DA, Stevens MJ. Interaction of metabolic and vascular factors in the pathogenesis of diabetic neuropathy. In: Hotta N, Greene DA, Ward DJ, Sima AAF, Boulton AJM, (eds.). Diabetic Neuropathy: New Concepts and Insights. Amsterdam, The Netherlands: Elsevier Science B.V. 1995;37-41.
6. Ward JD. Diabetic neuropathy. In: KGMM Alberti, RA DeFronzo, H Keen, P Zimmet (eds.). International Textbook of Diabetes Mellitus. Chichester: John Wiley and Sons Ltd. 1992;59:1385-414.
7. Tesfaye S, Harris N, Jakubowski JJ et al. Impaired blood flow and arteriovenous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993;36: 1266-74.
8. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
9. Boulton AJM (ed.). Diabetic Neuropathy. Carnforth, UK: Marius Press, 1997;41-61.
10. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999;42:773-88.
11. Kempler P, Tesfaye S, Chaturvedi N et al. The EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002;19:900-09.
12. Gottsäter A, Ahmed M, Fernlund P, Sundkvist G. Autonomic neuropathy in type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. Diabet Med 1999;16:49-54.
13. Szelag B, Wroblewski M, Castenfors J et al. Obesity, microalbuminuria, hyperinsulinemia and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care 1999;22:1907-08.
14. Valensi P, Paries J, Lormeau B, Assad N, Attali JR. Cardiac parasympathetic changes: a new component of the insulin resistance syndrome. Diabetes 1999;48(suppl 1):A149(abstract).
15. Ziegler D. Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment. Diabetes Metab Rev 1994;10:339-83.
16. Hendrickse MT, Thuluvath PJ, Triger DR. The natural history of autonomic neuropathy in chronic liver disease. Lancet 1992;339:1462-4.
17. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997;15:13-17.
18. Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. Diabetologia 1997;40:476-81.
19. Jermendy G, Tóth L, Vörös P, Koltay MZ, Pogátsa G. QT-interval in diabetic autonomic neuropathy. Diabet Med 1990;7:750.
20. Kempler P, Váradi A, Szalay F, Tamás GY. Autonomic neuropathy and corrected QT interval prolongation: there is a relationship. Diabetes Care 1994;17:454-6.
21. Kempler P, Váradi A, Szalay F. Autonomic neuropathy and prolongation of QT-interval in liver disease. Lancet 1992;340:318.
22. Kempler P, Keresztes K, Hermányi ZS, Marton A. Studies must establish whether prolonged QTc interval in newly diagnosed type 1 diabetes is reversible. BMJ 1998;317:678-9.
23. Krahulec B, Strobová L, Balal̈ovjech I. Hypertension is a prominent feature of diabetic autonomic neuropathy. a 10-year follow-up study. Diabetologia 1996;39(suppl 1):36A(abstract).
24. Spallone V, Maiello MR, Cicconetti E, Menzinger G. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non-insulin-dependent diabetes. Diab Res Clin Pract 1997;34:169-79.
25. Maser RE, Pfeifer MA, Dorman JS, Kuller RH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Arch Intern Med 1990;150:1218-22.
26. Kempler P, Hermányi Zs, Keresztes K, Marton A. Klinische und prognostische Bedeutung der kardialen autonomen Neuropathie. In: Gries FA, Federlin K, (eds.). Benfotiamin in der Therapie von Polyneuropathien. Stuttgart-New York: Thieme Verlag, 1998:39-44.
27. Gambardella S, Frontoni S, Spallone V et al. Increased left ventricular mass in normotensive diabetic patients with autonomic neuropathy. Am J Hypertens 1993;6:97-102.
28. Jermendy GY, Ferenczy J, Hernandez E, Farkas K, Nádas J. Day-night blood pressure variation in normotensive and hypertensive NIDDM patients with asymptomatic autonomic neuropathy. Diabetes Res Clin Pract 1996;34:107-14.
29. Jermendy GY. Sympathovagal balance and cardiovascular diseases in diabetic patients with autonomic neuropathy. Diab Nutr Metab 1995;8: 123-4.
30. Vinik AI, Zola BE. The effects of diabetic autonomic neuropathy on the cardiovascular system. In: Schwartz CJ, Born GVR, (eds.). New Horizons in Diabetes Mellitus and Cardiovascular Disease. London, UK: Current Science Ltd, 1995:159-71.
31. Beck MO, Silveiro SP, Friedman R, 'Clausell N, Gross JL. Asymptomatic coronary artery disease is associated with cardiac autonomic neuropathy and diabetic nephropathy in type 2 diabetic patients. Diabetes Care 1999;22:1745-7.
32. Airaksinen KEJ. Silent coronary artery disease in diabetes - a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001;44:259-66.
33. Valensi P, Sachs RN, Harfouche B et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24:339-43.
34. Kleiger RE, Miller JP, Bigger JT, Moss AJ and the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.
35. Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. JACC 1993;21:729-36.
36. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ, for the ATRAMI Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-84.
37. Lengyel CS, Török T, Várkonyi T, Kempler P, Rudas L. Baroreflex sensitivity and heart-rate variability in insulin-dependent diabetics with polyneuropathy. Lancet 1998;351:1436-7.
38. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. BMJ 1982;285:916-18.
39. American Diabetes Association, American Academy of Neurology: Consensus statement. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11:592-6.
40. Valensi P, Attali JR, Gagant S and the French Group for Research and Study of Diabetes Neuropathy. Reproducibility of parameters for assessment of diabetic neuropathy. Diabet Med 1993;10:933-9.
41. Ewing DJ, Marty CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experiences in diabetes. Diabetes Care 1985;8:491-8.
42. Kempler P, Tesfaye S, Chaturvedi N et al. The EURODIAB IDDM Complications Study Group. Blood pressure response to standing in the diagnosis of autonomic neuropathy: the EURODIAB IDDM Complications Study. Arch Physiol Biochem 2001;109:215-22.
43. Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes. Diabetes Care 2000;23:241-7.
44. Naas AAO, Davidson NC, Thompson C et al. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent: cohort study. BMJ 1998;316:745-6.
45. Lengyel CS, Thury A, Várkonyi T et al. Disturbances of heart rate variability and spatial and circadian QT intervals in diabetic patients with cardiac autonomic neuropathy. Hung Arch Int Med 1997;50:431-8.
46. 123I-MIBG myocardial scintigraphy and power spectral analysis of heart rate variability. Diabetic Med 1996;13:266-72.
47. Schnell O, Muhr D, Dresel S et al. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients. Diabetologia 1996;39:970-5.
48. Kempler P, Váradi A, Tamás GY. Autonomic neuropathy in newly diagnosed diabetes mellitus. Diabetes Care 1993;16:848-9.
49. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial. Diabetologia 1998;41:416-23.
50. 123I] metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998;41:443-51.
51. Watkins PJ. Clinical observations and experiments in diabetic neuropathy. Diabetologia 1992;35:2-11.
52. Kempler P (ed.). Neuropathies. Nerve Dysfunction of Diabetic and Other Origin. Budapest, Hungary: Springer Verlag, 1997.
53. Ziegler D, Mühlen H, Rathmann W, Gries FA. Effects of one year's treatment with gamma-linolenic acid (EF4) on diabetic neuropathy. Diabetes 1993;42(suppl 1):99A(abstract).
54. Johansson BL, Fernquist-Forbes E, Odergren T, Remahl S, Wahren J. C-peptide improves automatic nerve function in IDDM patients. Diabetologia 1996;39:687-95.
55. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996;220:113-19.
56. Bitsch R, Wolf M, Möller J, Heuzeroth L, Grüneklee D. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivate. Ann Nutr Metab 1991;35:292-6.
57. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996;104:311-16.
58. Koltai MZ, Pósa I, Winkler G, Kocsis E, Pogátsa G. The preventive effect of benfotiamine on the development of cardiac autonomic neuropathy in diabetic dogs. Hung Arch Int Med 1997;50:443-8.
59. Nagamatsu M, Mickander KK, Schmelzer JD et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18: 1160-7.
60. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ. Improvement of insulin-stimulated glucose disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996;104:284-8.
61. Ziegler D, Hanefeld M, Ruhnau KJ et al. The ALADIN Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3 week multicenter randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425-33.
62. Ziegler D, Schatz H, Conrad F, Ulrich H, the DEKAN Study Group, Reichel G, Gries FA. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NlDDM patients. Diabetes Care 1997; 20:369-73.
63. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107:421-30.